Inve
IN ⇄ US

Aarti Drugs share price & results

Aarti Drugs· Healthcare

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Global API manufacturer making bulk drugs, formulations and specialty chemicals across 14 plants in Gujarat, Maharashtra and Himachal Pradesh.

Company research is public. Sign in to keep your own companies, notes and cases.

Inve AI Signals on AARTIDRUGS
Direct bridge to live research & tools watching Aarti Drugs
Guidance Hit Rate
22 targets · 30% hit rate 3 achieved · 12 active →
Segment Shift
Sector & Mix Compare sector growth & peers →
Reverse DCF
Implied Growth Test priced-in growth in DCF tool →
Concall & Tone
Q1 FY27 analysed Read claims, qualifiers & Q&A →

Price & Snapshot

₹445.15 −2.34% · −₹10.65

Last close 5 Nov 2026 · NSE · INR · Source: Inve

Performance −11.6% 1Y

₹350₹400₹450₹500Nov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 4 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 3 Aug 2026

1Y: ₹503.6 on 4 Nov 2025 → ₹445.15. High ₹520.5 (10 Nov 2025), low ₹319.75 (30 Mar 2026).

Previous close
₹455.8
Market cap
₹4.1k Cr
52-week range
₹319.75 – ₹520.5
One year
−11.61%
Price to earnings (TTM to Sept 2026)
17.67×
Return on equity (TTM to Sept 2026)
13.74%

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue27.0 ₹ crore+200.0% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin16.0 %+3.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit83.0 ₹ crore+84.4% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity13.74 %+0.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.16 %+0.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)15.05 %+13.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

3 of 10 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Aarti Drugs management guidance track record on Inve: 22 targets tracked across analysed earnings calls (3 achieved, 7 missed, 12 open).

Delivering on Capex (1/1 achieved), while Growth (1 needs watch) is lagging.

TargetOriginal wordingSaidLatest callVerdict
Capex Project CommissioningCommence operations in Q3 FY25
Call transcript, Q2 FY25 · 2 Nov 2024		Q2 FY25Q1 FY27:The plant is confirmed to be operating at nearly 65% utilization, confirming the promise remains fulfilled, albeit with the initial delay.
Call transcript, Q1 FY27 · 3 Aug 2026		Achieved*
Growth Long-term RevenueINR 4,200 crores to INR 4,500 crores
Call transcript, Q2 FY25 · 2 Nov 2024		Q2 FY25Q1 FY27:The long-term consolidated revenue target for FY27 was not mentioned for the fifth consecutive quarter.
Call transcript, Q1 FY27 · 3 Aug 2026		Ghosted
Growth Volume Growth15% to 20%
Call transcript, Q2 FY26 · 10 Nov 2025		Q2 FY26Q1 FY27:Management firmed up guidance, stating 'for next two years, we are very well poised for that 10% to 15% kind of a volume growth', revising guidance back up from the 'strive for 8-10%' comment.
Call transcript, Q1 FY27 · 3 Aug 2026		Revised Up

Source: Inve Guidance Tracker for Aarti Drugs · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of Aarti Drugs's 22 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 19 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Sector context

Sector call context

Shared sector pressures matched to this company’s latest reporting period.

Similar pressures reported by peers

Tailwind coverage is not available yet.

Similar commentary provides sector context; it does not establish a business relationship with Aarti Drugs. Each comparison matches a headwind disclosed by Aarti Drugs in the same calendar reporting quarter.

  • Continued pressure from higher raw material prices and elevated freight costs, though the…

    Topic: Freight and shipping · Logistics supply chain · Q1 FY27

    Aarti Drugs reported: Continued pressure from higher raw material prices and elevated freight costs, though the company's operating models have shown resilience.

    Reporting period ended 2026-06-30

    8 other companies · Logistics supply chain

    Divi's Laboratories Limited (DIVISLAB) reported (period ended 2026-06-30): Elevated freight rates, container/ISO tank availability issues, port congestion, and extended transit times continue.

    Zydus Lifesciences Limited (ZYDUSLIFE) reported (period ended 2026-06-30): Sharp QoQ increase in operating costs due to acquisition-driven impacts (Zylidac, Assertio) and freight expenses, though management states it's factored into guidance.

    IPCA Laboratories Limited (IPCALAB) reported (period ended 2026-06-30): Freight rates have significantly increased (e.g., 3x for South America, ~2x for US/Europe) and container availability is difficult, though management states this is accounted for.

    Rubicon Research Limited (RUBICON) reported (period ended 2026-06-30): Gross margin increased despite sequential increase in key input and freight costs, managed through tactical measures.

    Evidence drawer

    Evidence type: Summary paraphrase

    Continued pressure from higher raw material prices and elevated freight costs, though the company's operating models have shown resilience.

    Source company: Aarti Drugs · Reporting period ended 2026-06-30 · Calendar quarter: Q1 FY27 · Distinct companies matched: 8

    Similar commentary provides sector context; it does not establish a business relationship.

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Live Summary

AARTIDRUGS ₹445.15 −2.34%
Guidance Verdict (22 tracked) 3 kept · 12 open· 7 missed
AI Call Brief · Q1 FY27

Aarti Drugs Q1 FY27

Overview

Symbol
NSE:AARTIDRUGS
Exchange
NSE
Currency
INR

What Aarti Drugs does

Based on the company's own presentations, annual report and earnings calls.

Aarti Drugs is a manufacturer of Active Pharmaceutical Ingredients (APIs), finished-dose formulations, and specialty chemicals/intermediates, operating a flexible in-house plus outsourced production model backed by in-house R&D. It holds global or India leadership in several high-volume molecules (Nimesulide, Ketoconazole, Metronidazole Benzoate, Tinidazole, Fluoroquinolones, Metformin), and diversified into formulations in 2014 through its wholly owned subsidiary Pinnacle Life Science. The company sells APIs, formulations and specialty chemicals to customers in over 100 countries, with regulated markets and exports forming a growing share of its business mix.

Segments

  • Active Pharmaceutical Ingredients (API)
  • Formulations
  • Specialty Chemicals, Intermediates & Others
Manufacturing facilities
14
Finished products
80+
API molecules produced
50+
Employees
2,200+
Countries with market presence
100+
API manufacturing units
9
Founded 1984Employees 2,200 (FY26) Company website

How the price took the results

Moved an average of ±3.9% across the last 4 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q1 FY273 Aug 2619 50+216.7%₹422.75 → ₹407.25−3.7%
Q4 FY2623 May 266 55−33.3%₹389.95 → ₹394.45+1.2%
Q3 FY264 Feb 268 41—₹390.6 → ₹370.9−5.0%
Q2 FY2610 Nov 259 45—₹491.45 → ₹520.5+5.9%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case for Aarti Drugs

Free account: one company. Everything above stays public.

Write why you follow Aarti Drugs and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Quick Answers

Frequently asked questions on Aarti Drugs

Compiled directly from AARTIDRUGS's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Aarti Drugs (AARTIDRUGS) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Aarti Drugs reported revenue of ₹27 Cr, net profit of ₹83 Cr, an operating margin of 16.0%. Diluted earnings per share stood at ₹9.09.

How is Aarti Drugs (AARTIDRUGS) valued today, and what growth does the stock price imply?

Aarti Drugs (AARTIDRUGS) trades at ₹445.15, with a market capitalization of ₹4.1k Cr.

Who owns Aarti Drugs (AARTIDRUGS) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 54.1%, FIIs hold 2.3%, DIIs hold 10.2%, Public shareholders hold 33.4%.

Learn to analyse Aarti Drugs

Guides on how to read this kind of business and the numbers that matter.